Prima adds three more experts to advisory board

Prima BioMed (ASX:PRR) has appointed three new gynaecological oncology experts to its clinical advisory board to help guide the development of ovarian cancer candidate CVac.

Professors Eric Pujade-Lauraine, Christian Marth and Ignace Vergote have joined the advisory board. All three new appointees have MDs and PhDs.

Pujade-Lauraine is founder of French gynaecological cancer research group Gineco and head of the Women Cancers and Clinical Research Department at Hopitaux Universitaires Paris Centre.

Marth is head of the Department of Obstetrics and Gynecology at Innsbruck Medical University, president and founder of the Austrian Association for Gynaecologic Oncology (AGO) and president elect and founder of the European Network of Gynaecological Oncological Trial Groups (ENGOT).

Vergote is head of the Department of Obstetrics and Gynaecology and Gynaecological Oncology at the Catholic University of Leuven, Belgium and chairman of the Flemish Society of Obstetrics and Gynaecology.

The new appointments come a month after Prima BioMed selected gynaecological oncologist Dr Bradley Monk to join the advisory board. The total size of the board has now increased to seven.

Prima BioMed is gearing up for a 210-patient trial of CVac in epithelial ovarian cancer. The company secured the first regulatory approvals for the trial last month, and expects to commence recruitment during the second calendar quarter.

Prima BioMed (ASX:PRR) shares were trading 5% higher at $0.042 as of around 1.30 pm on Wednesday.